Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease through percutaneous cardiovascular interventions.
Improving the quality of life and reducing sudden cardiac death by limiting the impact of heart rhythm disturbances.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practicing in specific cardiology domains.
BARCELONA, Spain – Saturday 30 August: Patients who took the anti-inflammatory drug colchicine just before cardiac surgery had a significantly lower risk of developing a common complication called post-pericardiotomy syndrome (PPS), according to a new study presented at the ESC 2014 Congress today.But the drug’s side-effects might be more trouble than its worth.Results of the Colchicine for Prevention of the Post-pericardiotomy Syndrome and post-operative atrial fibrillation (COPPS-2) trial were presented as a Hot Line at the congress.
“There was a high rate of gastrointestinal side effects in the study and this is a concern,” noted study investigator Massimo Imazio, MD, from Maria Vittoria Hospital in Torino, Italy. “It suggests that the drug should be considered only in well-selected patients.”“What surprised me was the overall good prognosis of PPS that we observed in the trial, suggesting that perhaps pre-surgical prevention may be unnecessary altogether,” he said. “Instead, early prevention immediately after cardiac surgery or early treatment of PPS seems preferable, since it appears to be better tolerated and have similar or better outcomes.”
PPS is a post-surgical reaction involving fever and inflammation around the heart and lungs. About one third of cardiac patients are affected by either PPS, post-operative atrial fibrillation (heart rhythm problems) or post-operative pericardial and/or pleural effusions (fluid around the heart) with the potential for prolonged hospital stays, increased readmissions, and possibly the need for invasive interventions.COPPS-2, a multicenter, double-blind, placebo-controlled, randomised clinical trial, looked at the potential of pre-operative administration of colchicine to prevent these three conditions in 360 consecutive cardiac surgery candidates from 11 centers in Italy. Patients (mean age 67 years, 69% male) were randomised to start placebo (n=180) or colchicine (n=180) between 48 and 72 hours before surgery and continue for one month after surgery. Dosing was 0.5 mg twice daily for patients weighing at least 70 kg, or once daily for patients weighing less.The main aim of the study was to determine the rate of PPS in the first three months after surgery, with secondary assessments of post-operative atrial fibrillation and effusions.The study found that PPS was significantly less common in the colchicine group compared to the placebo group (19.4% vs. 29.4%; p=0.030; relative risk [RR] 0.66), but medication did not reduce the incidence of the post-operative atrial fibrillation or post-operative effusions.However when drug withdrawals due to gastrointestinal side-effects were removed from the analysis patients who could tolerate the drug had a lower rate of post-operative atrial fibrillation compared to those on placebo (RR 0.65; p=0.012).Adverse event rates were higher in the colchicine group (20.0% vs. 11.7%; RR 1.89; p=0.034), largely as a result of increased gastrointestinal intolerance (RR 2.17; p=0.020).However overall rates of study drug discontinuation were similar and relatively high for both groups (about 20%), with no serious adverse events observed. COPPS-2 comes on the heels of the first COPPS trial which showed a similar benefit of colchicine, but when given after, rather than before cardiac surgery. The big difference between the two trials is that the first trial showed no increase in adverse events compared to placebo.
“We observed more side effects in COPPS-2, probably because patients are more susceptible in the perioperative period, when the common use of antibiotics and proton pump inhibitors greatly increases the risk of gastrointestinal side effects,” said Professor Imazio.“We hypothesised that in COPPS-2, an earlier start for the drug, with more gradual dosing might improve both efficacy and compliance, but instead it just increased gastrointestinal side effects.”
At present, colchicine is not approved for the prevention of the PPS in North America or Europe, and its use is off-label for this indication. It is currently approved for the treatment of gout and Familial Mediterranean Fever.ESC TV: Watch Dr. Massimo Imazio's interview
SOURCES OF FUNDING: The COPPS-2 trial was supported by former Azienda Sanitaria 3 of Torino (now ASLTO2) within the Italian National Health Service. Acarpia (Madeira, Portugal) provided the study drug and placebo as an unrestricted institutional grant and had no role in planning of the study, analysis of data, or writing of the manuscript. FAR.G.IM. srl (Catania, Italy) provided funding to support insurance costs for the trial. No other extramural funding was used to support this work. DISCLOSURES: The investigators report no conflicts of interestAbout the European Society of CardiologyThe European Society of Cardiology (ESC) represents more than 80 000 cardiology professionals across Europe and the Mediterranean. Its mission is to reduce the burden of cardiovascular disease in Europe. About ESC Congress 2014The ESC Congress is currently the world's largest international congress in cardiovascular medicine. The spotlight of this year's event is “innovation and the heart”. ESC Congress 2014 takes place from 30 August to 3 September at the Fira Gran Via in Barcelona, Spain. For more information on ESC Congress 2014 contact the ESC Press Office.To access all the scientific resources from the sessions during the congress, visit ESC Congress 365. This press release accompanies both a presentation and an ESC press conference at the ESC Congress 2014. Edited by the ESC from material supplied by the investigators themselves, this press release does not necessarily reflect the opinion of the European Society of Cardiology. The content of the press release has been approved by the presenter.
Our mission: To reduce the burden of cardiovascular disease
© 2017 European Society of Cardiology. All rights reserved